NSE · ONESOURCE · Pharmaceuticals
Onesource Specl Pharma Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹446 Cr with net profit ₹51 Cr — a 11.47% net margin, versus 5.13% the period before.
Shareholding
As of 2026-06-30
- Promoter30.48%
- Public26.95%
- FII19.19%
- DII23.38%
77,899 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.92× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #20 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,73,629 Cr | 38.11 | 5.67 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,20,143 Cr | 216.48 | 3.49 | 11.27% | 14% |
| Lupin Limited | ₹1,12,127 Cr | 70.41 | 4.99 | 23.76% | 19.4% |
| Zydus Lifesciences Ltd. | ₹1,12,000 Cr | 20.62 | 4.13 | 18.59% | 18.86% |
| Mankind Pharma Limited | ₹1,08,077 Cr | 194.71 | 6.63 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,478 Cr | 345.42 | 18.19 | 16.77% | 13.05% |
| Dr Reddys Laboratories Ltd. | ₹95,369 Cr | 431.17 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,231 Cr | 100.13 | 2.43 | 9.25% | 10.5% |
| Biocon Ltd. | ₹70,007 Cr | 546.71 | 2.06 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹68,056 Cr | 287.91 | 4.92 | 16.66% | 15.65% |
| Onesource Specl Pharma Limited(this company) | ₹19,792 Cr | 4316 | 3.39 | -0.01% | -0.05% |
AI analysis
AI-generated · google/gemini-2.5-flashOnesource Specl Pharma Limited is listed on the Indian markets with a market capitalization of Rs 18907 Cr. The company reported revenue of Rs 1462.33 Cr for the year ending March 2025.
Positives
- +The institutional holding (DII + FII) is 38.1079% as of March 31, 2026, indicating significant investment by institutions.
- +The debt-to-equity ratio of 0.21 is relatively low.
- +Revenue for the fiscal year ended March 2025 was Rs 1462.33 Cr.
Negatives
- −The company reported negative earnings per share (EPS) of Rs -1.57.
- −The return on equity (ROE) is 0%, indicating no profit generated for shareholders' equity.
- −Return on capital employed (ROCE) is low at 0.5473%.
- −Promoter holding decreased from 34.2539% on March 31, 2025, to 30.4831% on March 31, 2026.
- −A significant portion of promoter shares, 38.38%, was pledged as of March 31, 2026.
Financial performance
For the year ended March 2025, Onesource Specl Pharma Limited generated revenue of Rs 1462.327 Cr and reported a net loss of Rs -17.971 Cr. Quarterly revenue for March 2026 was Rs 428.22 Cr, with a net profit of Rs 4.6 Cr. This follows a net loss of Rs -88.7 Cr on revenue of Rs 290.34 Cr in December 2025.
Profitability & returns
The company recorded an EPS of Rs -1.57, reflecting a net loss. The return on equity (ROE) is 0%, and the return on capital employed (ROCE) is 0.5473%. These figures indicate challenges in generating profits relative to equity and capital employed.
Balance sheet
The company's debt-to-equity ratio stands at 0.21, indicating a reliance on debt for financing. The book value per share is Rs 513.9, which represents the net asset value attributable to shareholders on a per-share basis.
Ownership & pledges
As of March 31, 2026, promoters held 30.4831% of the company's shares. Public shareholding was 31.409%, while Domestic Institutional Investors (DII) held 20.6093% and Foreign Institutional Investors (FII) held 17.4986%. A significant portion of promoter holdings, 38.38%, was pledged.
Shareholding Changes
Promoter holding decreased from 34.2539% in March 2025 to 30.4831% in March 2026. Conversely, DII holding increased from 18.0353% to 20.6093% over the same period. FII holding also slightly increased from 18.5411% to 17.4986% from March 2025 to March 2026.
Data as of — price: 2026-07-29 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Onesource Specl Pharma Limitedshare price & fundamentals